secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyteir Therapeutics, Inc. (—)
CIK:        0001662244
Form:       8-K/A
Filed at:   2023-02-03T23:59:59+00:00
Accession:  0000950170-23-001771
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyteir cuts 70% of workforce, focuses CYT-0851 on ovarian cancer; cash runway to 2026
--------------------------------------------------------------------------------

- Workforce reduced by ~70% to 15 or fewer employees; expects $2.5M-$3M severance charges in Q1 2023.
- CEO Markus Renschler eligible for retention bonus of 150% of target annual bonus if employed through Dec 31, 2023.
- CBO Andrew Gengos separating Feb 3, 2023; CSO Paul Secrist separating Apr 1, 2023; stock options accelerated.
- Phase 2 monotherapy enrollment suspended; focus on CYT-0851 + capecitabine for platinum-resistant ovarian cancer.
- Cash and cash equivalents $147M as of Dec 31, 2022 (unaudited); estimated cash runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/0000950170-23-001771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662244/000095017023001771/cyt-20230112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-001771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer